CoChat
Sign Up
Cited by 2

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

L-type calcium channel antagonist isradipine age-dependently decreases plaque associated dystrophic neurites in 5XFAD mouse model

Wickline, Jessica L., Smith, Sabrina, Shin, Riley, Odfalk, Kristian, Sanchez, Jesse, Javors, Martin, Ginsburg, Brett, Hopp, Sarah C.·2023·Neuropharmacology
DOI 10.1016/j.neuropharm.2023.109454PMC PMC9987839
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuropharm.2023.109454

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • LAMP1 is mislocalized to dystrophic neurites in 5XFAD models and in human Alzheimer's disease.

    “membrane protein 1 (LAMP1) is mislocalized to dystrophic neurites in 5XFAD models (Forner et al., 2021;Gowrishankar et al., 2015;Wickline et al., 2023) and human AD (Barrachina et al., 2006).”

    From Hippocampal TMEM55B overexpression in the 5XFAD mouse model of Alzheimer's disease (2024) · cites this paper as Wickline et al., 2023

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 79

  1. 2022, 18, 700
  2. Arispe, 1993, Alzheimer disease amyloid β protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum, Proc. Natl. Acad. Sci. U.S.A., 90, 567, 10.1073/pnas.90.2.567 · DOI
  3. Bachmeier, 2011, Selective dihydropyiridine compounds facilitate the clearance of β-amyloid across the blood–brain barrier, Eur. J. Pharmacol., 659, 124, 10.1016/j.ejphar.2011.03.048 · DOI
  4. Berridge, 2010, Calcium hypothesis of Alzheimer's disease, Pflugers Arch. Eur. J. Physiol., 10.1007/s00424-009-0736-1 · DOI
  5. Bezprozvanny, 2008, Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease, Trends Neurosci., 31, 454, 10.1016/j.tins.2008.06.005 · DOI · Paper page
  6. Bolmont, 2008, Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance, J. Neurosci., 28, 4283, 10.1523/JNEUROSCI.4814-07.2008 · DOI · Paper page
  7. Brawek, 2013, Microglial calcium signaling in the adult, aged and diseased brain, Cell Calcium, 53, 159, 10.1016/j.ceca.2012.12.003 · DOI
  8. Brawek, 2014, Impairment of in vivo calcium signaling in amyloid plaque-associated microglia, Acta Neuropathol., 127, 495, 10.1007/s00401-013-1242-2 · DOI
  9. Busche, 2008, Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease, Science, 321, 1686, 10.1126/science.1162844 · DOI · Paper page
  10. Carrara, 1994, Influence of input rates on (+/-)-isradipine haemodynamics and concentration-effect relationship in healthy volunteers, Eur. J. Clin. Pharmacol., 46, 29, 10.1007/BF00195912 · DOI
  11. Catterall, 2011, Voltage-gated calcium channels, Cold Spring Harbor Perspect. Biol., 3, 1, 10.1101/cshperspect.a003947 · DOI · Paper page
  12. Colton, 1994, K+ modulation of microglial superoxide production: involvement of voltage-gated Ca2+ channels, Am. J. Physiol. Cell Physiol., 10.1152/ajpcell.1994.266.6.C1650 · DOI
  13. Condello, 2015, Microglia constitute a barrier that prevents neurotoxic protofibrillar Aβ42 hotspots around plaques, Nat. Commun., 6, 10.1038/ncomms7176 · DOI · Paper page
  14. Copenhaver, 2011, A translational continuum of model systems for evaluating treatment strategies in Alzheimer's disease: isradipine as a candidate drug, Dis. Model. Mech., 4, 634, 10.1242/dmm.006841 · DOI
  15. Daschil, 2014, Short- and long-term treatment of mouse cortical primary astrocytes with β-amyloid differentially regulates the mRNA expression of L-type calcium channels, Pharmacology, 93, 24, 10.1159/000357383 · DOI · Paper page
  16. Dickson, 1999, Neurochemical diversity of dystrophic neurites in the early and late stages of alzheimer's disease, Exp. Neurol., 156, 100, 10.1006/exnr.1998.7010 · DOI
  17. Disterhoft, 2006, Pharmacological and molecular enhancement of learning in aging and Alzheimer's disease, J. Physiol., 99, 180
  18. Espinosa-Parrilla, 2015, The L-type voltage-gated calcium channel modulates microglial pro-inflammatory activity, Mol. Cell. Neurosci., 10.1016/j.mcn.2014.12.004 · DOI
  19. Facchinetti, 2006, Nimodipine selectively stimulates beta-amyloid 1-42 secretion by a mechanism independent of calcium influx blockage, Neurobiol. Aging, 27, 218, 10.1016/j.neurobiolaging.2005.02.006 · DOI
  20. Flanigan, 2014, Abnormal vibrissa-related behavior and loss of barrel field inhibitory neurons in 5xFAD transgenics, Gene Brain Behav., 13, 488, 10.1111/gbb.12133 · DOI · Paper page
  21. Forner, 2021, Systematic phenotyping and characterization of the 5xFAD mouse model of Alzheimer's disease, Sci. Data, 81, 1
  22. Gholami Pourbadie, 2016, Calcium channel blockade attenuates abnormal synaptic transmission in the dentate gyrus elicited by entorhinal amyloidopathy, Synapse, 70, 408, 10.1002/syn.21915 · DOI
  23. Ghoweri, 2020, Electrophysiological and imaging calcium biomarkers of aging in male and female 5×FAD mice, J. Alzheim. Dis., 78, 1419, 10.3233/JAD-200109 · DOI
  24. Gowrishankar, 2015, Massive accumulation of luminal protease-deficient axonal lysosomes at Alzheimer's disease amyloid plaques, Proc. Natl. Acad. Sci. U.S.A., 112, E3699, 10.1073/pnas.1510329112 · DOI · Paper page
  25. Guzman, 2018, Systemic isradipine treatment diminishes calcium-dependent mitochondrial oxidant stress, J. Clin. Invest., 128, 2266, 10.1172/JCI95898 · DOI
  26. Hansen, 2018, Microglia in Alzheimer's disease, J. Cell Biol., 217, 459, 10.1083/jcb.201709069 · DOI · Paper page
  27. Hegg, 2000, β-Chemokines and human immunodeficiency virus type-1 proteins evoke intracellular calcium increases in human microglia, Neuroscience, 98, 191, 10.1016/S0306-4522(00)00101-9 · DOI
  28. Hickman, 2008, Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice, J. Neurosci., 28, 8354, 10.1523/JNEUROSCI.0616-08.2008 · DOI · Paper page
  29. Hoffman, 2009, Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons, Neurology, 72, 1720, 10.1212/01.wnl.0000345881.82856.d5 · DOI
  30. Hopp, 2021, Targeting microglia L-type voltage-dependent calcium channels for the treatment of central nervous system disorders, J. Neurosci. Res., 99, 141, 10.1002/jnr.24585 · DOI
  31. Hopp, 2015, Calcium dysregulation via L-type voltage-dependent calcium channels and ryanodine receptors underlies memory deficits and synaptic dysfunction during chronic neuroinflammation, J. Neuroinflammation, 12, 10.1186/s12974-015-0262-3 · DOI
  32. Ilijic, 2011, The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson’s disease, Neurobiol. Dis., 43, 364, 10.1016/j.nbd.2011.04.007 · DOI
  33. Isaacs, 2006, Acceleration of amyloid β-peptide aggregation by physiological concentrations of calcium, J. Biol. Chem., 281, 27916, 10.1074/jbc.M602061200 · DOI
  34. Ishii, 2019, Amyloid-beta modulates low-threshold activated voltage-gated L-type calcium channels of arcuate neuropeptide Y neurons leading to calcium dysregulation and hypothalamic dysfunction, J. Neurosci., 39, 8816, 10.1523/JNEUROSCI.0617-19.2019 · DOI
  35. Kaczorowski, 2011, Mechanisms underlying basal and learning-related intrinsic excitability in a mouse model of Alzheimer's disease, Neurobiol. Aging, 32, 1452, 10.1016/j.neurobiolaging.2009.09.003 · DOI
  36. Kang, 2012, CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease, Nat. Commun., 31, 1
  37. Khachaturian, 1987, Hypothesis on the regulation of cytosol calcium concentration and the aging, Brain. Neurobiol. Aging, 8, 345, 10.1016/0197-4580(87)90073-X · DOI
  38. Kim, 2011, Effects of amyloid-β peptides on voltage-gated L-type CaV1.2 and CaV1.3 Ca2+ channels, Mol. Cell, 32, 289, 10.1007/s10059-011-0075-x · DOI
  39. Koschak, 2001, Alpha 1D (Cav1.3) subunits can form l-type Ca2+ channels activating at negative voltages, J. Biol. Chem., 276, 22100, 10.1074/jbc.M101469200 · DOI
  40. Kuchibhotla, 2008, Aβ plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks, Neuron, 59, 214, 10.1016/j.neuron.2008.06.008 · DOI · Paper page
  41. LaFerla, 2002, Calcium dyshomeostasis and intracellular signalling in alzheimer's disease, Nat. Rev. Neurosci., 311, 862, 10.1038/nrn960 · DOI
  42. Lee, 2011, Lysosomal proteolysis inhibition selectively disrupts axonal transport of degradative organelles and causes an alzheimer’s-like axonal dystrophy, J. Neurosci., 31, 7817, 10.1523/JNEUROSCI.6412-10.2011 · DOI
  43. Leussis, 2006, Habituation in rodents: a review of behavior, neurobiology, and genetics, Neurosci. Biobehav. Rev., 30, 1045, 10.1016/j.neubiorev.2006.03.006 · DOI · Paper page
  44. Li, 2009, Nimodipine protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation, Neuropharmacology, 56, 580, 10.1016/j.neuropharm.2008.10.016 · DOI
  45. Lipscombe, 2004, L-type calcium channels: the low down, J. Neurophysiol., 10.1152/jn.00486.2004 · DOI
  46. Liu, 2020, Verapamil extends lifespan in Caenorhabditis elegans by inhibiting calcineurin activity and promoting autophagy, Aging (Albany NY), 12, 5300, 10.18632/aging.102951 · DOI
  47. López-Arrieta, 2000, Nimodipine for primary degenerative, mixed and vascular dementia, Cochrane Database Syst. Rev., CD000147
  48. Lopez, 2008, Increased intraneuronal resting [Ca2+] in adult Alzheimer's disease mice, J. Neurochem., 105, 262, 10.1111/j.1471-4159.2007.05135.x · DOI · Paper page
  49. McBrayer, 2013, Lysosome and calcium dysregulation in alzheimer's disease – partners in crime, Biochem. Soc. Trans., 41, 1495, 10.1042/BST20130201 · DOI
  50. Morich, 1996, Nimodipine in the treatment of probable alzheimer's disease: results of two multicentre trials, Clin. Drug Invest., 11, 185, 10.2165/00044011-199611040-00001 · DOI
  51. Mu, 2008, Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis, PLoS Biol., 6, e26, 10.1371/journal.pbio.0060026 · DOI
  52. Nair, 2016, A simple practice guide for dose conversion between animals and human, J. Basic Clin. Pharm., 7, 27, 10.4103/0976-0105.177703 · DOI · Paper page
  53. Park, 2014, Pharmacological correction of obesity-induced autophagy arrest using calcium channel blockers, Nat. Commun., 51 5, 1
  54. Pierrot, 2006, Calcium-mediated transient phosphorylation of tau and amyloid precursor protein followed by intraneuronal amyloid-β accumulation, J. Biol. Chem., 281, 39907, 10.1074/jbc.M606015200 · DOI
  55. Querfurth, 1997, Caffeine stimulates amyloid β-peptide release from β-amyloid precursor protein-transfected HEK293 cells, J. Neurochem., 69, 1580, 10.1046/j.1471-4159.1997.69041580.x · DOI
  56. Querfurth, 1994, Calcium ionophore increases amyloid/3 peptide production by cultured Cells1, Biochemistry, 33, 4550, 10.1021/bi00181a016 · DOI
  57. Reverchon, 2020, Hippocampal interleukin-33 mediates neuroinflammation-induced cognitive impairments, J. Neuroinflammation, 17, 1, 10.1186/s12974-020-01939-6 · DOI
  58. Rio, 2010, Purification of RNA using TRIzol (TRI reagent), Cold Spring Harb. Protoc., 10.1101/pdb.prot5439 · DOI
  59. Rosales Jubal, 2021, Acitretin reverses early functional network degradation in a mouse model of familial Alzheimer's disease, Sci. Rep., 111, 1
  60. Rubinsztein, 2005, Autophagy and its possible roles in nervous system diseases, Damage and Repair, 1, 11
  61. Sadleir, 2022, Oral nimodipine treatment has no effect on amyloid pathology or neuritic dystrophy in the 5XFAD mouse model of amyloidosis, PLoS One, 17, 10.1371/journal.pone.0263332 · DOI
  62. Sanz, 2012, Nimodipine inhibits IL-1β release stimulated by amyloid β from microglia, Br. J. Pharmacol., 167, 1702, 10.1111/j.1476-5381.2012.02112.x · DOI
  63. Sharoar, 2019, Sequential formation of different layers of dystrophic neurites in Alzheimer's brains, Mol. Psychiatr., 249, 1369, 10.1038/s41380-019-0396-2 · DOI · Paper page
  64. Siddiqi, 2019, Felodipine induces autophagy in mouse brains with pharmacokinetics amenable to repurposing, Nat. Commun., 101, 1
  65. Silei, 1999, Activation of microglial cells by PrP and β-amyloid fragments raises intracellular calcium through L-type voltage sensitive calcium channels, Brain Res., 10.1016/S0006-8993(98)01272-4 · DOI
  66. Strodel, 2010, Transmembrane structures for Alzheimer's Aβ1-42 oligomers, J. Am. Chem. Soc., 132, 13300, 10.1021/ja103725c · DOI
  67. Stutzmann, 2007, The pathogenesis of Alzheimers disease - is it a lifelong “calciumopathy”, Neuroscientist, 13, 546, 10.1177/1073858407299730 · DOI
  68. Sukoff Rizzo, 2020, Improving preclinical to clinical translation in Alzheimer's disease research, Alzheimer’s Dement. Transl. Res. Clin. Interv., 6
  69. Tollefson, 1990, Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia, Biol. Psychiatr., 27, 1133, 10.1016/0006-3223(90)90050-C · DOI
  70. Tse, 1987, Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man, Eur. J. Clin. Pharmacol., 32, 361, 10.1007/BF00543970 · DOI
  71. Tse, 1989, Bioavailability of isradipine in young and old rats: effect of mode of administration, J. Pharm. Pharmacol., 41, 657, 10.1111/j.2042-7158.1989.tb06554.x · DOI
  72. Uchida, 1997, Brain pharmacokinetics and in vivo receptor binding of 1,4-dihydropyridine calcium channel antagonists, Life Sci., 61, 2083, 10.1016/S0024-3205(97)00881-3 · DOI
  73. Vianna, 2000, Role of hippocampal signaling pathways in long-term memory formation of a nonassociative learning task in the rat, Learn. Mem., 7, 333, 10.1101/lm.34600 · DOI
  74. Vitek, 2020, Translational animal models for alzheimer's disease: an alzheimer's association business consortium think tank, Alzheimer’s Dement. Transl. Res. Clin. Interv., 6
  75. Wang, 2019, Blockade of microglial Cav1.2 Ca2+ channel exacerbates the symptoms in a Parkinson's disease model, Sci. Rep., 9
  76. Weiss, 1994, Rapid communication: Ca2+ channel blockers attenuate β-amyloid peptide toxicity to cortical neurons in culture, J. Neurochem., 62, 372, 10.1046/j.1471-4159.1994.62010372.x · DOI
  77. Xiao, 2015, Neuronal-targeted TFEB accelerates lysosomal degradation of app, reducing Aβ generation and amyloid plaque pathogenesis, J. Neurosci., 35, 12137, 10.1523/JNEUROSCI.0705-15.2015 · DOI · Paper page
  78. Yao, 2020, Limiting RyR2 open time prevents alzheimer's disease-related neuronal hyperactivity and memory loss but not β-amyloid accumulation, Cell Rep., 32, 10.1016/j.celrep.2020.108169 · DOI
  79. Yue, 2006, 3, 139

Cited by

Sorted by citations

Metadata

Authors
Wickline, J. L., Smith, S., Shin, R., Odfalk, K., Sanchez, J., Javors, M., Ginsburg, B., & Hopp, S. C.
ORCID
Venue
Neuropharmacology
Publisher
Elsevier BV
Published
2023-04
Volume
227
Pages
109454
ISSN
0028-3908
DOI
10.1016/j.neuropharm.2023.109454
PMC
PMC9987839
Cited by
2
References
12
Language
en
Licence
Funders
  • National Institute on Aging (K01 AG066747)
  • National Institutes of Health

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review